Get the Stockscreener App
27.51
1.54%
-0.43
Celldex Therapeutics Inc stock is traded at $27.51, with a volume of 638.01K.
It is down -1.54% in the last 24 hours and up +13.44% over the past month.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
See More
Previous Close:
$27.94
Open:
$28.02
24h Volume:
638.01K
Relative Volume:
0.70
Market Cap:
$1.83B
Revenue:
$5.79M
Net Income/Loss:
$-199.61M
P/E Ratio:
-9.1395
EPS:
-3.01
Net Cash Flow:
$-188.48M
1W Performance:
-6.59%
1M Performance:
+13.44%
6M Performance:
+35.18%
1Y Performance:
+4.01%
1-Day Range:
$27.29
$28.14
1-Week Range:
$27.29
$30.50
52-Week Range:
$14.40
$30.50
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Name
Celldex Therapeutics Inc
Sector
Industry
Phone
908-200-7500
Address
53 FRONTAGE ROAD, HAMPTON
Compare CLDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
27.51 | 1.86B | 5.79M | -199.61M | -188.48M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Oct-13-25 | Initiated | Barclays | Underweight |
| Apr-28-25 | Initiated | Canaccord Genuity | Buy |
| Mar-20-25 | Initiated | Morgan Stanley | Overweight |
| Feb-13-25 | Initiated | UBS | Buy |
| Oct-07-24 | Initiated | Citigroup | Buy |
| Sep-30-24 | Initiated | Goldman | Neutral |
| Sep-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-18-24 | Initiated | Stifel | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Dec-20-23 | Initiated | TD Cowen | Outperform |
| Nov-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Aug-22-23 | Initiated | Wells Fargo | Underweight |
| Sep-17-21 | Initiated | Jefferies | Buy |
| Sep-10-21 | Initiated | SVB Leerink | Outperform |
| Jul-22-21 | Initiated | Guggenheim | Buy |
| Feb-21-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-07-16 | Initiated | Aegis Capital | Buy |
| Mar-08-16 | Downgrade | Jefferies | Buy → Hold |
| Mar-07-16 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Mar-07-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-01-16 | Initiated | H.C. Wainwright | Buy |
| Aug-11-15 | Reiterated | Brean Capital | Buy |
| Aug-11-15 | Reiterated | Oppenheimer | Outperform |
| Aug-11-15 | Reiterated | ROTH Capital | Buy |
| Jun-02-15 | Reiterated | WBB Securities | Strong Buy |
| Nov-17-14 | Reiterated | ROTH Capital | Buy |
| Mar-04-14 | Reiterated | Oppenheimer | Outperform |
| Jul-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Feb-26-13 | Reiterated | Oppenheimer | Outperform |
| Jan-10-13 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-02-12 | Reiterated | Oppenheimer | Outperform |
| Sep-14-12 | Reiterated | Cantor Fitzgerald | Buy |
View All
Celldex Therapeutics Inc Stock (CLDX) Latest News
TFG Asset Management GP Ltd Has $6.43 Million Stake in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Bellevue Group AG Has $67.31 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Eventide Asset Management LLC Lowers Stake in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Celldex Therapeutics, Inc. $CLDX Shares Sold by Redmile Group LLC - MarketBeat
HighVista Strategies LLC Purchases New Position in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Down 4.5%Should You Sell? - MarketBeat
Celldex Therapeutics (CLDX) Valuation After Launching Second Global Phase 3 Program for Barzolvolimab - Sahm
Celldex Therapeutics Initiates Global Phase 3 Trial for Barzolvolimab in Cold Urticaria, Symptomatic Dermographism - marketscreener.com
Celldex initiates phase 3 trial for cold urticaria and dermographism drug - Investing.com Canada
Celldex Initiates Global Registrational Phase 3 Program Of Barzolvolimab In Cold Urticaria And Symptomatic Dermographism - TradingView — Track All Markets
Celldex (NASDAQ: CLDX) begins Phase 3 ColdU, SD trial after positive Phase 2 - Stock Titan
19,627 Shares in Celldex Therapeutics, Inc. $CLDX Purchased by Bollard Group LLC - Defense World
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Manila Times
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month HighHere's Why - MarketBeat
Does Celldex Therapeutics Inc (CLDX) offer a good opportunity for investors? - setenews.com
Celldex Therapeutics stock hits 52-week high at $29.14 By Investing.com - Investing.com Nigeria
How Celldex Therapeutics Inc. (TCE2) stock stacks up against competitorsJuly 2025 Levels & Stepwise Entry and Exit Trade Signals - Newser
Can Celldex Therapeutics Inc. (TCE2) stock sustain institutional flowsInflation Watch & Consistent Return Investment Signals - Newser
Celldex Therapeutics stock hits 52-week high at $29.14 - Investing.com
Fisher Asset Management LLC Sells 49,420 Shares of Celldex Therapeutics, Inc. $CLDX - Defense World
American Century Companies Inc. Grows Position in Celldex Therapeutics, Inc. $CLDX - Defense World
Can Celldex Therapeutics Inc. (TCE2) stock sustain revenue momentumPortfolio Return Summary & Risk Adjusted Buy and Sell Alerts - Newser
Is Celldex Therapeutics Inc. (TCE2) stock testing key supportWeekly Trend Summary & Safe Capital Growth Plans - Newser
Will Celldex Therapeutics Inc. stock outperform international peersWeekly Risk Report & Stepwise Entry/Exit Trade Alerts - Newser
Imvax Gets Positive Overall Survival Data From Phase IIb GBM Asset - Citeline News & Insights
Why Celldex Therapeutics Inc. (TCE2) stock gets analyst attention2025 Key Lessons & Expert Approved Momentum Trade Ideas - Newser
Why Celldex Therapeutics Inc. (TCE2) stock is listed among top recommendationsWeekly Risk Summary & Long-Term Capital Growth Ideas - Newser
Is Celldex Therapeutics Inc. (TCE2) stock a buy during volatile marketsJuly 2025 EndofMonth & Fast Momentum Entry Tips - Newser
Evercore Healthcare Conference - marketscreener.com
Geode Capital Management LLC Has $34.05 Million Stake in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Block Trades: Is Celldex Therapeutics Inc. stock supported by innovation pipelineMarket Trend Review & Short-Term Trading Opportunity Alerts - moha.gov.vn
Precision Trading with Celldex Therapeutics Inc. (CLDX) Risk Zones - news.stocktradersdaily.com
Segall Bryant & Hamill LLC Invests $7.89 Million in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics Hits Day High with Strong 7.72% Intraday Surge - Markets Mojo
Eczema Pipeline Drugs Landscape Report 2025: MOA Analysis, R&D Progress, Clinical Trial Pipeline, and Strategic Market Evolution - The Globe and Mail
How Investors May Respond To Celldex Therapeutics (CLDX) Leadership Change and Widening Third-Quarter Losses - Sahm
A look into Celldex Therapeutics Inc (CLDX)’s deeper side - Setenews
Will Celldex Therapeutics Inc. (TCE2) stock see insider accumulationDip Buying & Reliable Entry Point Alerts - newser.com
Can Celldex Therapeutics Inc. (TCE2) stock reach $200 price targetGDP Growth & Verified Trade Idea Suggestions - newser.com
Why Celldex Therapeutics Inc. stock could be next big winnerRisk Management & Reliable Entry Point Trade Alerts - newser.com
Real time social sentiment graph for Celldex Therapeutics Inc.2025 Key Lessons & High Accuracy Investment Signals - newser.com
Celldex Therapeutics Hits Day High with 9.61% Surge in Stock Price - Markets Mojo
What risks investors should watch in Celldex Therapeutics Inc. stockWeekly Gains Summary & AI Forecast for Swing Trade Picks - newser.com
Celldex Therapeutics, Inc. $CLDX Shares Bought by TSP Capital Management Group LLC - MarketBeat
Celldex Therapeutics Inc. stock momentum explained2025 Sector Review & Low Risk High Reward Ideas - newser.com
Does Celldex Therapeutics Inc. qualify in momentum factor screening - newser.com
How to use a screener to detect Celldex Therapeutics Inc. breakoutsTrade Signal Summary & Free Safe Capital Growth Stock Tips - newser.com
What’s next for Celldex Therapeutics Inc. stock price2025 Breakouts & Breakdowns & Low Risk Investment Opportunities - newser.com
What momentum shifts mean for Celldex Therapeutics Inc.2025 Institutional Moves & Safe Swing Trade Setup Alerts - newser.com
Celldex Therapeutics Inc Stock (CLDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):